RxDoctor Payments Data

Amber Whitton-Smith, NP

Nurse Practitioner · Denver, CONPI 1689823593

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,084 of the $7,131 with a category attached, or 85.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,131in general payments, 2019–2025

Across 289 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$813
  • Novartis$395
  • AstraZeneca$373
  • Pfizer$319
  • Seagen Inc.$294
  • Gilead$288
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$6,08485%
  • Education$1,04715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)26$813
Novartis19$395
AstraZeneca(2 entities)18$373
Pfizer17$319
Seagen Inc.7$294
Gilead12$288
E.r. Squibb & Sons, L.L.C.12$275
Lilly USA, LLC8$258
Pharmacyclics LLC, An Abbvie Company6$235
Daiichi Sankyo Inc.11$229
GSK9$226
AVEO Pharmaceuticals, Inc.6$220
Sanofi8$212
Sobi, Inc7$212
Merck10$204
Bristol Myers Squibb9$196
Exelixis Inc.4$176
Genentech USA, Inc.8$165
Karyopharm Therapeutics Inc.6$153
Rigel Pharmaceuticals, Inc.6$124
Genmab U.S., Inc.4$112
Astellas Pharma US Inc4$104
Eisai Inc.5$101
Amgen5$100
Tersera Therapeutics LLC5$99
Sanofi-aventis U.S. LLC1$87
Regeneron Healthcare Solutions, Inc.3$69
Beigene USA, Inc.3$68
Pharmaessentia USA Corporation3$63
Ipsen Biopharmaceuticals, Inc3$57
Alnylam Pharmaceuticals Inc.3$57
ADC Therapeutics America, Inc.3$56
CTI Biopharma Corp.2$53
Takeda Pharmaceuticals U.S.A., Inc.2$52
Recordati_rare_diseases_inc.2$47
Incyte Corporation2$40
Immunocore Limited2$39
Beone Medicines USA, Inc.2$37
AbbVie1$33
Monteris Medical Corporation1$31
Myriad Genetic Laboratories, Inc.1$31
Taiho Oncology, Inc.2$30
Sumitomo Pharma America, Inc.1$25
Springworks Therapeutics, Inc.1$25
EUSA Pharma (US) LLC1$24
Mirati Therapeutics, Inc.1$23
Dendreon Pharmaceuticals LLC1$23
Blueprint Medicines Corporation1$22
Stemline Therapeutics Inc.1$22
Sun Pharmaceutical Industries Inc.1$20
EMD Serono, Inc.1$20
Servier Pharmaceuticals LLC1$18
Tempus AI, Inc1$18
Foundation Medicine, Inc.1$18
Dova Pharmaceuticals1$18
Pharmacosmos Therapeutics Inc.1$17
TG Therapeutics, Inc.1$17
Organon1$17
Morphosys, US Inc.1$17
Boehringer Ingelheim1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,131 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$14,326
Medicare patients
136
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide31$578,429
Lenalidomide27$357,978
ImbruvicaIbrutinib14$107,936
EliquisApixaban22$19,083
Gabapentin18$1,623
Anastrozole42$686
Letrozole20$509
Dexamethasone15$254
Ondansetron Hcl14$179
Prochlorperazine Maleate15$96
Prednisone16$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$196$578,42931 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$235$107,93614 claims
PfizerEliquis$319$19,08322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →